The killer cell immunoglobulin-like receptors (KIRs) comprise a gene family that is highly polymorphic and rapidly evolving. To aid in understanding the evolutionary dynamics shaping this family, we have studied the genomic organization of the KIR region in the chimpanzee and the orangutan. Previous analysis of expressed KIR genes in these species has shown conservation of all major KIR lineages although the number and nature of KIR within in each lineage varies.
The killer immunoglobulin-like receptor (KIR) genes are a compact cluster of genes located in human chromosome 19q13.4. Polymorphic variation within the known genes is now emerging, indicating allelic diversity for each KIR gene. A method identifying KIR 3DL2 allele variation based on PCR-SSOP has been developed for the discrimination of 12 named 3DL2 alleles (3DL2*001 -*012). Nucleotide sequence submissions, were retrieved from the GenBank databank (www.ncbi.nlm.nih.gov) and aligned to aid primer and probe selection. Two regions of the 3DL2 gene were specifically amplified in separate PCR products (approx. 1440 & 348 base pairs respectively), the larger product containing exon 3 through to exon 4 of the KIR 3DL2 gene, with the smaller product containing exon 8 through to exon 9. The combined products were challenged with a total of twenty digoxigenin labelled probes, designed from the amplified 3DL2 regions.
Application of this method to a Northern Irish healthy control group (n=162), has shown good allele diversity within this gene with identification of 10/12 alleles (3DL2*004 & *012 not identified). 3DL2*001 and *002 were identified as the most common alleles in this Caucasian group, occurring at equal frequencies (20.3%). Three ambiguous heterozygous combinations remain following SSOP typing (3DL2*001, *011 from *003, 3DL2*010; *001, *007 from *006, *010; 3DL2*003, *007 from *006, *011). Due to sequence complications these combinations would also be difficult to resolve using alternative methods such as SSP and SBT. The method has also been applied to the 13th IHW NK cell line panel (n=84), twelve CEPH families (n=48), also from the NK component of the 13th IHW, and eight Northern Irish families (n=42). The 3DL2 alleles segregated as expected within all family units. Investigation of 2 Northern Irish individuals and 4 cell lines, producing unusual SSOP patterns is currently underway. In addition to the variable gene content observed within killer immunoglobulin-like receptor (KIR) genes, significant allelic diversity is now emerging. A PCR-SSOP method identifying KIR 2DL4 allele variation has been developed. PCR products (approx. 1440 base pairs) containing the D0 and D2 domains of the KIR 2DL4 gene were specifically generated with primers flanking this region. Sixteen digoxigenin labelled probes were designed to provide distinct discrimination of 10 possible 2DL4 variant alleles.
NOVEL KIR GENE DUPLICATION IDENTIFIED THROUGH PCR-SSOP
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The application of the 2DL4 allele system has identified individuals (n=11) possessing three alleles of this gene. This event has been confirmed by isolating three distinct allele clones in each individual, which sequenced as the alleles identified by SSOP. Investigation of the full KIR types of these individuals reveals a common connection with respect to our previously reported 3DS1/3DL1 three allele event1. It is our assumption that a cross over event has occurred between differing KIR haplotypes resulting in the duplication of the 2DL4, 3DS1/3DL1 genes, and others, on the newly formed haplotype. Interestingly, the 2DL4 type of child within a 13th IHW CEPH family did not initially agree with family inheritance. DNA cloning and sequencing was performed, confirming the SSOP type. Three 2DL4 alleles have now been identified in the mother of this child -SSOP identified two of these alleles with the third allele hidden within the SSOP pattern. The presence of three maternal alleles explains the typing of the offspring. This highlights a problem when typing for 2DL4 alleles -the gene duplication occurs in 1% of individuals tested and the third allele may not always be apparent with SSOP typing alone.
The typing method was applied to a Northern Irish healthy control group (n=162), identifying only five of the ten alleles (2DL4*00201, *00202, *005, *006 & *007). The same five alleles were again observed as the only 2DL4 alleles present within the 13th IHW NK cell line panel (n=84), twelve 13th IHW CEPH families (n=48) and forty Northern Irish families (n=220). The five alleles segregated as expected within all family units. The remaining 2DL4 alleles were not detected in various other population groups studied (Omani, Hong Kong, Cuban Mulatto, South African Xhosa). Therefore it seems likely that the other five allele sequences not detected in this study represent rare alleles or sequence artefacts. The rhesus macaque (Macaca mulatta) is an important animal model in studies on chronic and infectious diseases. In contrast to humans, sequence analysis of exon 2 of Mamu-DRB genes from pedigreed rhesus macaques showed a high degree of polymorphism regarding number and content of -DRB genes per haplotype. However, little is known about the expression or functionality of these genes. Until now, only three cDRB sequences have been published and the cDRA gene was thought to be monomorpic. Therefore, Mamu-cDRA sequences were analysed in B-cell lines of 12 consanguinious, as well as homozygous and heterozygous rhesus macaques with known Mhc haplotypes. A total of at least 8 different cDRA alleles could be distinguished, resulting in 4 distinct gene products. The amino acid differences have been found in the leader peptide and in the cytoplasmatic tail, whereas the alpha 1 domain with the antigen-binding positions remains invariant. Furthermore, from 10 B-cell lines of consanguinious, as well as homozygous and heterozygous rhesus macaques, 19 distinct cDRB alleles have been determinend. This indicates that the analysed rhesus macaques express one, two, or three -DRB genes per haplotype. These full length cDRA and cDRB sequences are needed to construct various tetrameric recombinant Mhc class II-peptide complexes as well as to establish transfectant cell lines, which are useful for HIV/SHIV and autoimmune disease studies.
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Genes and Immunity (2003) Exon 2 of the polymorphic Mamu -DPB1, -DQA1, -DQB1 and -DRB loci has been analysed from 173 pedigreed rhesus macaques from the BPRC's breeding colony. Most of the animals or their ancestors originate from India. The panel also includes animals from Burma, China, and even some of unknown origin, and mixed breeds. MtDNA variation appears to correlate with the abovedescribed geographic origin. In this panel a large number of Mamu class II alleles is observed. The 15 different -DPB1 alleles are largely shared between monkeys from different origins whereas in the human situation particular alleles appear to be unique for ethnic populations. In contrast to -DPB1, the highly polymorphic Mamu-DQA1/DQB1 alleles form extremely tight-linked pairs that are for two third population specific. For most of the DQA1/DQB1 haplotypes, 33 -DRB region configurations present on the same chromosome have been determined resulting in 40 different -DQ/DRB haplotypes. All of these distinct DQ/DRB haplotypes appear to be specific for monkeys from a certain origin. Thus, in evolutionary terms, the Mamu-DP, -DQ, and -DR regions show an increasing instability resulting in population specific class II haplotypes. 
THE "NON-CLASSICAL" MIC GENE IN CHIMPANZEES
INTRON SEQUENCES OF DQA1: AS POLYMORPH AS THE EXONS
Christina EM Voorter and Ella M van den Berg-Loonen Tissue Typing Laboratory, University Hospital Maastricht, NL.
Sequencing of DQA1 has revealed that the polymorphism is not restricted to exon 2. Thirteen out of 22 alleles can only be distinguished on basis of the sequences of exons 1, 3 or 4. To assess the degree of polymorphism outside the exons the sequences of introns 1 and 2 were determined. For sequencing, cell lines were used that are homozygous for DQA1. The intron sequences of 13 DQA1 alleles were determined, comprising 5/9 *01 alleles, *0201, 2/3 *03 alleles, *0401, 3/6 *05 alleles and *0601. Of intron 1 250 nucleotides of the sequence were determined by reverse sequencing, whereas the complete sequence of intron 2 was obtained by forward sequencing using 2 different sequencing primers. The sequences revealed major differences between the different allele groups, but also within one allele group. Especially the allele DQA1*0103 showed several mismatches with the other DQA1*01 alleles in both introns 1 and 2. The length of intron 2 varied between 412 and 445 nucleotides, due to two insertions in the DQA1*03 allele group. The intron sequence of DQA1*0201 resembled the sequence of the *03 alleles, except for these insertions, and this reflects the situation of the exons. Also the sequences of DQA1*0401 and *0601 showed a high degree of similarity, with only 5 nucleotide differences in introns 1 and 2, and 2 in the exons. This implicates a very close evolutionary relationship between these alleles, questioning the separation in two different allele groups. Elucidation of the intron sequences of DQA1 showed that the percentage of polymorphic sites of introns 1 and 2 is comparable to that of exon 2. Furthermore, it enables the development of gene-and/or group-specific primers to be used for advanced sequencing strategies.
DNA MICROARRAY TECHNOLOGY FOR HLA-CLASS I TYPING
Cinzia Pera˚ §, Erika Inglese˚, and Giovanni Battista Ferrara˚ § National Cancer Institute L.go R. Benzi 10, Genova ITALY; §University of Genoa, Viale Benedetto XV, Genova ITALY The possibility to use DNA microarray technology in biomedical research enable us to study and research polymorphisms spread in human genome. Our approach has been performed selecting oligos that contain the mismatch at the 3' end, and spotting them onto a particularly treated glass surface. The selected oligos hybridize with the DNA-sequence-target (in particular the locus specific PCR product for HLA-A, -B and -C loci), and a single base extension reaction is performed, using a mix of ddNTPs labelled with CY3 or CY5. This strategy allowed us the identification of known sequence variants differing by as little as a single nucleotide. The approach is based on the discriminating power of the oligonucleotides, spotted onto the glass slides, each of them having a perfect match or a mismatch with the specific PCR product. The reading was made by an in-house Cw/Laser Scanning and analyzed with software processing. Using this simple two-laser scanner, it was possible to determine where real positive reaction occured and obtain the desired information regarding the genotype of the samples. The intensity of the fluorescence on spotted oligonucleotides probes was analyzed by ourself developed software program. This software automatically detects spots, removes the background and design the virtual array, generating matrixes which, in excel format, can be used for determining the HLA typing. The easiness in carrying-out and obtaining the typing results elects this approach as a method of choice in transplantation. Sequence-based typing (SBT) methods for HLA-B are based on elucidation of exon 2 and 3 sequences. Extension of the method with sequences of other exons occurs more and more frequently. This has led to an increase of ambiguities with alleles having identical exon 2 and 3 sequences, but differences in other exons. At the moment, 24 HLA-B alleles show such an ambiguity that can be resolved by sequencing the exon in which the difference is located. In this study we describe a reliable solid-phase SBT strategy for heterozygous sequencing of exons 1, 4 and 5 in addition to the previously described exons 2 and 3. Exon 1 was amplified separately, whereas exons 4 and 5 were amplified together. One forward sequencing reaction was sufficient to obtain reliable results for exons 1 and 5. For exon 4 in some instances two different sequencing primers were needed to obtain the complete heterozygous sequence.
A panel of 21 individuals, carrying alleles from 33 different allelic groups, were typed for exons 1, 4 and 5 to validate the SBT protocol. No allelic dropout or preferential amplification was noticed in these individuals. In addition, the SBT protocol was used to resolve ambiguities in 27 individuals. Three individuals with ambiguity B*0705/06 were typed B*0706 in two cases and *0705 in one. The other ambiguous combinations studied were B*1512/19, B*180101/17N, B*270502/0504/13, B*350101/40N/ 42, B*390101/0103, B*400102/0101, B*440201/19N/27 and B* 510101/11N/30/32/0105. In all cases sequencing revealed the first allele to be present. The described highresolution SBT protocol for sequencing exons 1, 4 and 5 is a valuable tool for resolving ambiguities of HLA-B alleles with differences in these exons as well as for studying the polymorphism of HLA-B outside exons 2 and 3.
HAPLOTYPE-SPECIFIC SEPARATION OF AMBIGUOUS ALLELE-PAIRS IN 8-& 96-WELL PARALLEL FORMAT
Johannes Dapprich1, Laurie Burdett2, Kirstin Smith2, Bin Tu2, Marcelo Fernandez-Vina2, Nancy Murphy3 1 Generation Biotech; 2 C.W. Bill Young Marrow Donor Program; 3 GenoVision, Inc.
Haplotype-Specific Extraction, HSE, establishes haplotypes from individual patient's samples without knowledge of familial information by physically separating a diploid sample into its haploid components:
Magnetic beads are selectively attached to polymorphic sites and used to isolate the targeted fragments from a heterozygous mixture, without requiring amplification. Haploseparated DNA is directly analyzed with kits and assays already in use for HLA-typing.
Haploseparations are carried out in an 8-well strip or 96-well microtiterplate format. This enables efficient, parallel processing of multiple samples; either in a fully manual manner or with increasing degrees of automation.
The method permits the unambiguous typing of diploid allele pair combinations that fail to be resolved by conventional sequence-based typing (SBT) and sequence-specific oligonucleotide probes (SSOP).
Shown are haplotype-specific separations targeting the major allele groups of the HLA-B locus, performed on genomic DNA.
The purification of alleles allows the unambiguous identification of a patient's haplotype and allele pair combination. Background: An exact estimation of haplotypes using genotypic data from unrelated individuals is sometimes incorrect. This is due to the diploidy of the human genome, making it difficult to determine the phase (cis/trans) of a given sequence variation in heterozygous individuals. Furthermore, variations in one copy of a chromosome (especially deletions, inserts, gene duplications) can be obscured by the normal sequence present on the other copy of the chromosome. Here we introduced a method to estimate extended haplotypes on monoallelic chromosomes derived from human diploid cells.
CLONING
Methods and Results: Peripheral human blood lymphocytes and cells of the mouse myeloma cell line X63-Ag 8.653 were mixed at an appropriate ratio and then fused in the presence of polyethylene glycol. Fused cells were selected for two weeks in medium containing hypoxanthin-aminopterin-thymidin and afterwards they were again selected in hypoxanthin-thymidin medium. Hybrids became visible within 4-6 weeks and were subsequently cloned by limiting dilution. Stable clones were subjected to genotyping of human micro satellite markers. The cloned hybrids lost randomly more than 50 % of the human chromosomes resulting in cell lines carrying monoallelic human chromosomes.
Conclusion: This method allows direct sequencing of monoallelic chromosomes. Thus, complex variability in certain haplotypes is accessible to definitive sequence determination. Furthermore, the extended haplotype structure can be determined in chromosomal regions of high linkage disequilibrium across large distances, e.g. the MHC region.
THE SBT ANALYSIS TOOL AT DBMHC/NCBI W. Helmberg, R.Dunivin, M. Feolo NCBI, Bethesda, USA In preparation for the presentation of IHWG data, the dbMHC, at NCBI has developed a public web based SBT interface tool for the analysis of haploid or diploid sequences.
Link: www.ncbi.nlm.nih.gov/IEB/Research/GVWG/MHC Input: Haploid or diploid sequences can be copied and pasted or uploaded from a file in fasta format. Multiple sequences from the same sample, but for different exons can be analyzed together. In addition, users may specify those sequences that are linked due to a common pre-amplification (e.g., exon2 and exon 3), Processing: Sequences are blasted against an allele database, which has been separated into exons and 5'utr for KIR. Thus cDNA and genomic DNA can be analysed with the same tool. Intron/exon boundaries are set based on the annotated boundaries of individual genes. Allele assignment can be done with a variable amount of nucleotide mismatches. Heterozygote sequences resulting from a sample with two alleles, which differ in length due to deletion/insertion events, are analysed correctly.
Output: Allele interpretation is listed in the order of nucleotide mismatches. Input sequences can be displayed with any allele from the locus of interest using the interactive link to the dbMHC alignment viewer. Links attached to the individual mismatches, provide navigation to mismatched positions within the alignment display. Sequences submitted for analysis are separated into exon/intron data. The result with its exon/intron boundaries can be downloaded in fasta format. The HLA allele database is based on the current IMGT/HLA database consisting of classical HLA , non classical HLA. Analysis of sequences from the KIR loci is also available. Additional polymorphic loci of interest can be included on request. These tools and resources have been developed to support research and routine in the HLA field.
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ANTIBODY ANALYSIS PROGRAM USING RECOMBINANT HLA REVEALS DISCONTINUOUS EPITOPES.
Mike Bunce1, Kathrine Schou1, Martin Barnardo1, Arend Mulder2, Ian Crosby1. 1Dynal Biotech Ltd, Bromborough, UK. 2Leiden University Medical Centre, Leiden, The Netherlands.
We have tested various HLA class I monoclonal antibodies with single recombinant HLA class I antigens immobilised on nitrocellulose membranes and analysed the results using a novel computer algorithm (XR1) that correlates antibody reactivity to both linear, and conformational epitopes. One of the aims of this investigation was to elucidate the rules for theoretical and experimentally deduced complex paratope epitope interactions; the data will be applied to construct a modified program for HLA antibody specificity analysis. XR1 analyses potential antibody epitopes by using both continuous and discontinuous sets of amino acids contained within the size of an antibody footprint. This philosophy allows for the detection of epitopes that rely on 3-D conformation such as those that combine residues on both -hel ices or combinations of side loops and helices. To refine the algorithm it was tested using well-defined MoAbs such as the HLA-B7/22/27/67/73+ve ME1 MoAb that crossreacts with HLA-B46. One solution (there are others) that XR1 suggested for this complex specificity is for a discontinuous primary epitope of R62-Q65-A71 that is influenced by P43-E45. Presence of R62-Q65-A71 with P43-M45, such as in B46, results in weaker reactivity, possibly due to restricted access to the primary epitope by the altered adjacent side loop. This type of 'fuzzy' epitope is also found in other MoAbs: screening of the HDG8D9 MoAb by immobilized recombinant HLA reveals a B35/51/18 specificity crossreacting with B52, B53 and B37: that can also be explained by an epitope that it is a combination of discontinuous residues at 43-45 and 62-71. These and other findings will be discussed. HLA class I molecules present peptides which are usually 8-10 amino acids in length, and which essentially contribute to the antigenicity of the molecule. For a variety of alleles, peptide motifs have been described, but few studies have addressed the question to which extent variants of the same allelic group differ in their peptide motifs. To answer this question for the HLA-A*66 group, we have sequenced the eluate of a recombinant A*6602 molecule, and compared it with peptide sequence data reported for A*6601. The truncated recombinant product of A*6602 was expressed in the HLA class I-deficient cell line LCL 721.221. Cell culture supernatant was purified by W6/32 affinity chromatography, peptides were isolated by acid elution, and the predominant peptide was isolated by RP-HPLC. By MALDI-TOF mass spectrometry its sequence was determined as KTKGSGFFV, representing a fragment of the human Ig chain C region. For A*6601, at position 2 of the bound peptide, T and V; and at position 9, R have been previously described as anchor residues, bound by pockets B and F, respectively. While deviations at position 9 also in A*6601 peptides have been described, position 2 corresponds to the anchor residue reported for A*6601. Both A*66 variants differ by position 163 (R E), shaping pockets A and B. Although this position has been described as critical regarding HLA class I allorecognition, the results suggest that in A*66 the R E exchange leaves the P2 anchor of the peptide unaffected. Thus, this variation appears not to alter significantly the binding characteristics of the A*66 pockets, which allows to expect a low allogenicity between A*6601 and A*6602. Although the causative role of the human histocompatibility antigen HLA-B27 in spondyloarthropathies is not understood, the molecule itself appears as the strongest predisposing factor for pathogenesis. The B*2709 subtype exhibits limited disease association and differs only at position 116 (His) of the heavy chain from the common, disease-associated subtype B*2705 (Asp116). Residue 116 occupies a crucial position within the F-pocket which accomodates the peptide C-terminus, suggesting that differential peptide binding by the subtypes could be related to F-pocket architecture and hence to disease development. To uncover the molecular basis for the differental disease association, we determined the crystal structures of both subtypes in complex with a model peptide (Hülsmeyer et al., J. Biol. Chem. 277, 2002, 47844-47853) and two naturally occurring peptides. In case of the model peptide, both subtypes exhibited very similar structures, but revealed subtle differences at the protein surface which could result in differential T-cell recognition. However, these findings still do not provide a clear explanation for the differential disease association at the atomic level, and might be related to the model character of the peptide. Therefore, we additionally crystallized B*2705 and B*2709 with two self-peptides. Although these are presented in the context of both subtypes, the presence of T-cells with activity against such peptides may be mainly observed in individuals typing as B*2705, suggesting that these individuals, but not those with B*2709, can possess T-cells which have not been appropriately deleted during thymic selection. The refinement of the crystal structures is still in progress, but it is already clear that one of the self-peptides adopts the canonical conformation when bound to B*2709, but shows two drastically The main weakness of the MHC peptide binding predictive models available is their inability to give an account of the interdepen-dence of the sequences properties within the peptide. Which amino acids are present at a particular position in the peptide must, to a certain degree, be determined by which amino acids are present at other positions in the peptide itself. Reducing the data to bipolar variables and using and propositional logic algorithm, the peptide subsets that bind to A*0201 and to B*27052 were analysed. In regard to A*0201 the following intrapeptide sequence dependecies were identified: 2T = f(4Q, 5V, 6P, 7F, 8S, 9V) , 1Y = f(4P, 5G, 6P, 7V, 8T, 9V), 1L = f(2L), 1I = f(4Q, 5V, 6P, 7F, 8S, 9V), 9L = f(1L, 3L, 4V, 6V, 7V), 1F = f(3Y, 4G), 2M = f(8G, 1Y), 2L = f(5G), 1S = f(4D, 7I), 1V = f(4G, 6L), 2I = f(4S), 2V = f(3M, 3I, 4P, 4Q), 6P = f(4P, 4Q, 4G, 1L, 3L, 4L, 5L, 6L, 7L, 8L, 9L), 3Y = f(2M, 1L, 1F, 4G, 2L), 3D = f(4Q, 4P, 4G, 4L, 6P), 3M = f(2M, 9V, 9L), 4P = f(5G, 6P, 7V, 6T), 4Q = f(5V, 6P, 7F, 8S, 9V). The A*0201 model showed a sensitivity of 90% and a specificity of 98% with new data. In regard to B*27052-bound peptides, a model was created with a sensitivity of 100% and a specificity of 99%. This model does not distinguish between the binding to HLA-B*2705 and to HLA-B*2709. It does distinguish, however, between binding peptides, on one hand, and peptides meeting the known binding characteristics for HLA-B*2705, but actually failing to bind experimentally, on the other hand. Usual methods assuming the independence of peptide amino acids in determining binding could not distinguish between the two groups. It was found that the interrelation of the amino acid at position 9 with the other amino acids played a more significant role.
COMPARATIVE PEPTIDE BINDING CHARACTERISTICS
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